Altum Research
Contributor since: 2015
Company: Altum research
Latest Articles
Clovis May 2018 Update
ChemoCentryx: Discounted, Underfollowed, And Misunderstood Biotech
Achillion, Omeros, Ra Rx, Reata, ChemoCentryx, And Others In The IgA Nephropathy Space
VistaGen - Nanocap CNS Drug Chasing Ketamine Fame
Clovis Is The Investor's PARPi Winner
Altum Is Launching Biotech Insider
Oh, Hi March
Finding Biotech Value In All-Time Highs
Altum's Antimicrobial Update: Scynexis, Cidara, Matinas
Will Marinus Pharmaceuticals Come Crashing Down In 2018?
Voyager Therapeutics: What You Should Know
Flexion - When Approvals Go Bad
Seres Bombs A Phase 1B But They Said It Was Positive, Time To Buy?
Seres Therapeutics Is Hiding A Volatile Catalyst
Scynexis Q2 - Steady As She Goes
ContraFect: Why Hasn't Anyone Else Done This Already?
Zymeworks: Synonymous With Best In Class?
Flexion Therapeutics: Flexin' Its Price Target
Scynexis: Is The Delay A Buying Opportunity?
Seres Therapeutics: The Light At The End Of The Tunnel
Scynexis: Why The Drop? Buy The Drop?
Corbus Pharmaceuticals: Past And Present
CytRx: The BASIC Chemistry
SCYNEXIS: The Low Hanging Fruit The CDC, WHO, And FDA Like To See
Continued Derisking And Data Should Help Heron Take Flight
Seres Therapeutics: A Matter Of Details
Scynexis: A Proven Drug With Much-Needed Market Analysis
Merger And Acquisition Target Entellus, And Our Reasoning Behind It
Traditional Pizza Delivery Is Going To Be Cannibalized
Pieris Pharmaceuticals: The Blockbuster In Antibody Mimetics
CytRx: Ok Science, Bad Past, Unknown Future
Facebook: The Social Standard - Initiating Coverage With A $155 Price Target